Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 17 July 2006. doi:10.1136/gut.2005.083691
Gut 2007;56:95-106
Copyright © 2007 BMJ Publishing Group Ltd & British Society of Gastroenterology

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
gut.2005.083691v1
56/1/95    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thompson, C C
Right arrow Articles by Costello, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, C C
Right arrow Articles by Costello, E

PANCREAS

Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility

C C Thompson1, F J Ashcroft1,*, S Patel1,*, G Saraga1, D Vimalachandran1, W Prime2, F Campbell3, A Dodson3, R E Jenkins4, N R Lemoine5, T Crnogorac-Jurcevic5, H L Yin6, E Costello1

1 Division of Surgery and Oncology, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK
2 Cancer Tissue Bank Research Centre, Department of Pathology, University of Liverpool, Liverpool, UK
3 Department of Pathology, University of Liverpool, Liverpool, UK
4 Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
5 Cancer Research UK Molecular Oncology Unit, Barts and the London School of Medicine and Dentistry, London, UK
6 University of Texas Southwestern Medical Centre, Dallas, Texas, USA

Correspondence to:
Correspondence to:
E Costello
Division of Surgery and Oncology, Royal Liverpool University Hospital, 5th Floor UCD Building, Daulby Street, University of Liverpool, Liverpool L68 3 GA, UK;ecostell{at}liv.ac.uk

Background: Previously, proteomic methods were applied to characterise differentially expressed proteins in microdissected pancreatic ductal adenocarcinoma cells.

Aims: To report that CapG and a related protein, gelsolin, which have established roles in cell motility, are overexpressed in metastatic pancreatic cancer; and to describe their pattern of expression in pancreatic cancer tissue and their effect on cell motility in pancreatic cancer cell lines.

Methods: CapG was identified by mass spectrometry and immunoblotting. CapG and gelsolin expression was assessed by immunohistochemical analysis on a pancreatic cancer tissue microarray and correlated with clinical and pathological parameters. CapG and gelsolin levels were reduced using RNA interface in Suit-2, Panc-1 and MiaPaCa-2 cells. Cell motility was assessed using modified Boyden chamber or wound-healing assays.

Results: Multiple isoforms of CapG were detected in pancreatic cancer tissue and cell lines. Immunohistochemical analysis of benign (n = 44 patients) and malignant (n = 69) pancreatic ductal cells showed significantly higher CapG staining intensity in nuclear (p<0.001) and cytoplasmic (p<0.001) compartments of malignant cells. Similarly, gelsolin immunostaining of benign (n = 24 patients) and malignant (n = 68 patients) pancreatic ductal cells showed higher expression in both compartments (both p<0.001). High nuclear CapG was associated with increased tumour size (p = 0.001). High nuclear gelsolin was associated with reduced survival (p = 0.01). Reduction of CapG or gelsolin expression in cell lines by RNAi was accompanied by significantly impaired motility.

Conclusions: Up regulation of these actin-capping proteins in pancreatic cancer and their ability to modulate cell motility in vitro suggest their potentially important role in pancreatic cancer cell motility and consequently dissemination.


Abbreviations: IQR, interquartile range; MALDI-TOF, matrix-assisted laser desorption/ionisation-time-of–flight; MTT, 3-(4, 5-dimethythiazol-2-yl-2, 5-diphenyltetrazolium bromide)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & British Society of Gastroenterology